Dobutamine is approved by the Food and Drug Administration (FDA) for short-term use in patients with decreased contractility due to heart failure or cardiac surgical procedures leading to cardiac decompensation. The agent has not been shown to give positive outcomes in the hospitalized or outpatient setting for patients with heart failure despite hemodynamically improving the patient’s condition.
Dobutamine can be used as temporary intravenous inotropic support until resolution of the acute inducing factors or the patient receives more definitive treatment, such as coronary revascularization, mechanical circulatory support, or heart transplant. Short-term intravenous inotropic support should be given to patients in cardiogenic shock to preserve systemic blood flow and protect from end-organ damage.
Dobutamine can reasonably be given in continuous intravenous form for inotropic support to bridge patients with late-stage heart failure, stage D, that is refractory to guideline-directed medical therapy until patients who are candidates for and awaiting cardiac transplantation or mechanical circulatory support receive the appropriate long-term treatment.
Continuous intravenous inotropic dobutamine support can reasonably be given in the short-term for those hospitalized patients with severe systolic dysfunction and presenting with a low blood pressure and a cardiac output that is significantly decreased, to preserve systemic blood flow and protect from end-organ damage.
Continuous intravenous inotropic dobutamine support can reasonably be given for the long-term in palliative patients with late-stage heart failure, stage D, who are not candidates for mechanical circulatory support or cardiac transplantation for symptomatic control, regardless of guideline-directed medical therapy.
Intravenous inotropic dobutamine can be given off-label to patients in order to induce pharmacological stress during stress echocardiography if patients are not able to perform an exercise stress test. 
Dobutamine is used as a pharmacological agent because of its inotropic effects on the myocardium through binding and activating the beta 1 receptors. The medication is indicated clinically for decompensated congestive heart failure because of the sympathomimetic effects. Dobutamine increases contractility which leads to decreased end-systolic volume and therefore larger stroke volume. The larger stroke volume leads to an increase in cardiac output of the heart. The changes in cardiac output allow for the baroreceptor mediated response to decrease the systemic vascular resistance and cause little to no change in the arterial blood pressure. In addition to the well-known beta 1 activity, dobutamine has been shown to have some beta 2 activity, which contributes to the reduction in the systemic vascular resistance, and alpha 1 activity, to an even lesser extent, whose vasoconstrictive effects are negated by the baroreceptor mediated response and beta 2 activity.
Dobutamine is administered via intravenous access for inotropic support in decompensated congestive heart failure and stress echocardiogram testing. The dosage for cardiac decompensation in heart failure can begin with one-half to one micrograms/kg/min and can be increased up to a maximum of 40 micrograms/kg/min. The lower doses of dobutamine can be prescribed at 2.5 to 5.0 micrograms/kg/min, and the higher end of dobutamine doses can be 5.0 to 20.0 micrograms/kg/min. The dose for the stress echocardiogram test is initiated at five micrograms/kg/min and can be increased in intervals of 10 micrograms/kg/min every 3 to 5 minutes until the target heart rate is reached. Dobutamine comes in a solution as a racemic mixture of both positive and negative enantiomers that is then administered intravenously. The positive enantiomer in the solution is predominately selective for the beta sympathetic receptors, mainly beta 1 and 2, whereas the negative enantiomer has been shown in studies to be selective for the alpha one receptors.
Dobutamine administration can lead to possible adverse reactions, mainly due to the sympathomimetic activity. Majority of patients taking this medication have experienced a rise in the systolic blood pressure of 10 to 20 mmHg. Majority of patients have experienced a 5 to 10 beats per minute increase in the heart rate. There have been reports of further increases in systolic blood pressure and heart rate. In about 10% of the patients, there can be a rise of 30 beats per minute or more in the heart rate, and in about 7.5% of patients there can be an increase of 50 mmHg or more in the systolic blood pressure. Patients with preexisting hypertension have been shown to be more susceptible to the adverse effects in systolic blood pressure when using dobutamine.
Dobutamine has been shown to increase the risk of rapid ventricular response in patients with preexisting atrial fibrillation. It has been recommended that these patients use a regimen of digoxin before starting dobutamine, in order to decrease the risk of developing atrial fibrillation with a rapid ventricular response. There has been an increased risk of developing premature ventricular beats during the administration of dobutamine. About 5% of patients experience premature ventricular beats.
Other adverse effects caused by this medication include hypotension rarely. While increases in systolic blood pressure is a common effect due to dobutamine, hypotension can occur, less frequently, due to the decreases in the systemic vascular resistance. It is recommended to decrease the dose or stop the medication, in order to reverse the hypotensive effects.
Phlebitis at the site of the intravenous administration can occur, but it an uncommon reaction. Dobutamine can rarely reduce the potassium concentrations to hypokalemic levels. Other rare adverse effects have occurred in one to three percent of the patients including nausea, headaches, chest pain, palpitations, and shortness of breath. Dobutamine contains sulfite, which can lead to reactions in rare patients with sulfite hypersensitivity.
Dobutamine use has been contraindicated, according to the Food and Drug Administration, in patients with a noted history of allergic reactions to either previous dobutamine use or any sulfite use. The medication is contraindicated in patients with a history of idiopathic hypertrophic sub-aortic stenosis.
Throughout administration of this medication, there should be continuous monitoring using electrocardiogram and blood pressure checks because dobutamine is typically given to unstable patients and can lead to serious effects quickly that need to be monitored and addressed. The dose of dobutamine can be reduced, or the medication can be stopped if the patient experiences adverse effects.
Dobutamine toxicity is rare, and half-life is short at 2 minutes. Symptoms are generally due to sympathetic overstimulation and can include chest pain, palpitations, headaches, tremors, shortness of breath, nausea, and vomiting.
Dobutamine is a medication used in the ICU to manage low blood pressure. While the drug is safe, its use has to be monitored as it has the potential to severely raise blood pressure and heart rate. Dobutamine is administered as an IV infusion by nurses; hence these professionals should know the dose and what parameters to monitor. Overall, the effects of dobutamine are short lived. As soon as the infusion is stopped, the hemodynamic parameters are reversed.
|||Currie GM, PHARMACOLOGY PART 4: NUCLEAR CARDIOLOGY. Journal of nuclear medicine technology. 2019 Feb 15; [PubMed PMID: 30770476]|
|||Mansencal N,Mustafic H,Hauguel-Moreau M,Lannou S,Szymanski C,Dubourg O, Occurrence of Atrial Fibrillation During Dobutamine Stress Echocardiography. The American journal of cardiology. 2019 Jan 31; [PubMed PMID: 30745020]|
|||Yuan Y,Huang B,Miao H,Liu X,Zhang H,Qiu F,Liu Z,Zhang Y,Dong H,Zhang Z, A [PubMed PMID: 30734585]|
|||Vaidya Y,Dhamoon AS, Myocardial Stunning and Hibernation 2018 Jan; [PubMed PMID: 30725711]|
|||Bomberg H,Bierbach B,Flache S,Novák M,Schäfers HJ,Menger MD, Dobutamine Versus Vasopressin After Mesenteric Ischemia. The Journal of surgical research. 2019 Mar; [PubMed PMID: 30691823]|
|||Kislitsina ON,Rich JD,Wilcox JE,Pham DT,Churyla A,Vorovich EB,Ghafourian K,Yancy CW, Shock - Classification and Pathophysiological Principles of Therapeutics. Current cardiology reviews. 2018 Dec 12; [PubMed PMID: 30543176]|
|||Ruf K,Wirbelauer J,Beissert A,Frieauff E, Successful treatment of severe arterial hypotension and anuria in a preterm infant with renal tubular dysgenesis- a case report. Maternal health, neonatology and perinatology. 2018; [PubMed PMID: 30598831]|
|||Alhayek S,Preuss CV, Beta 1 Receptors 2018 Jan; [PubMed PMID: 30422499]|
|||Maack C,Eschenhagen T,Hamdani N,Heinzel FR,Lyon AR,Manstein DJ,Metzger J,Papp Z,Tocchetti CG,Yilmaz MB,Anker SD,Balligand JL,Bauersachs J,Brutsaert D,Carrier L,Chlopicki S,Cleland JG,de Boer RA,Dietl A,Fischmeister R,Harjola VP,Heymans S,Hilfiker-Kleiner D,Holzmeister J,de Keulenaer G,Limongelli G,Linke WA,Lund LH,Masip J,Metra M,Mueller C,Pieske B,Ponikowski P,Ristic A,Ruschitzka F,Seferovic PM,Skouri H,Zimmermann WH,Mebazaa A, Treatments targeting inotropy. European heart journal. 2018 Oct 8; [PubMed PMID: 30295807]|